Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic

  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

155.50 +2.39 (+1.56%)
Official Closing Price Updated: 7:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Kenvue Set To Pop Like A Tylenol Gelcap? Golden Cross Looms On Stock Chart
Kenvue Inc., owner of major brands like Tylenol, is poised for a technical knockout with a Golden Cross pattern and legal win. 
Via Benzinga
Dell, CoStar, PayPal And A Major Health Care Stock On CNBC's 'Final Trades'
Bill Baruch of Blue Line Capital named Dell Technologies Inc. his "final trade" on CNBC's "Halftime Report." 
Via Benzinga
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
Via Benzinga
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
From Johnson & Johnson
Via Business Wire
Johnson & Johnson Raises Talc Settlement Offer to $9B, Moves Closer to Settlement Victory
Johnson & Johnson boosts talc settlement offer to $9 billion, gaining support from key lawyer Allen Smith for quicker claimant payouts. 
Via Benzinga
Analyzing NYSE:JNJ's Dividend Potential.
Why JOHNSON & JOHNSON (NYSE:JNJ) qualifies as a good dividend investing stock. 
Via Chartmill
Will JOHNSON & JOHNSON Break Out? A Technical Analysis Perspective.
A technical analysis of JOHNSON & JOHNSON (NYSE:JNJ) shows it may be setting up for a breakout. 
Via Chartmill
Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration
The global psychedelic drugs market is projected to grow by USD 1.37 billion by 2028, driven by mental health needs and AI advancements in drug development. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
2 Dividend Stocks With Payouts That May Not Be as Safe as They Seem
Johnson & Johnson and Altria Group are two prominent dividend stocks, but I wouldn't rely on their payouts. 
Via The Motley Fool
Court Orders Johnson & Johnson To Compensate Auris Health Shareholders $1B
Johnson & Johnson is ordered to pay $1 billion in damages to Auris Health shareholders for breaching a 2019 merger agreement. The ruling finds Johnson & Johnson failed to support critical technology,... 
Via Benzinga
3 Dividend Stocks to Double Up on Right Now
These companies have excellent records of growing their dividends. 
Via The Motley Fool
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
Despite Medicare's first-ever negotiated drug prices under the Inflation Reduction Act, U.S. costs remain significantly higher than those in other wealthy nations, with some prices still more than... 
Via Benzinga
Topics Economy
Exposures Interest Rates
Competitor Analysis: Evaluating Johnson &amp; Johnson And Competitors In Pharmaceuticals Industry
Via Benzinga
Spotlight on Johnson & Johnson: Analyzing the Surge in Options Activity
Via Benzinga
Critical Insights From Johnson & Johnson Analyst Ratings: What You Need To Know
Via Benzinga
Is Johnson & Johnson the Best Dividend Stock for You?
You won't find a more dependable dividend payer on Wall Street. But whether it's the best stock for you depends on other factors. 
Via The Motley Fool
Worried About a Stock Market Sell-Off? Consider Coca-Cola, Pepsi, and These 3 Safe Dividend Kings for Decades of Passive Income.
Via The Motley Fool
Johnson & Johnson-Spin Off Kenvue Wins Lawsuit Over Pain Killer Tylenol 'Rapid Release' Gelcaps
Kenvue defends against a consumer lawsuit alleging that its Tylenol "Rapid Release" gelcaps did not relieve pain faster than regular tablets. A federal judge ruled the claims were preempted by FDA... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal Product Safety
Elliott Wave Technical Analysis: Johnson & Johnson - Friday, Aug. 30
JNJ appears to be in the latter stages of wave {iii} of 1. 
Via Talk Markets
Johnson & Johnson's Golden Cross: A Bullish Prescription For Investors?
Johnson & Johnson (NYSE:JNJ) achieves Golden Cross, signaling shift to bullish trend. Stock at $164.43, above all key moving averages & with positive catalysts ahead. 
Via Benzinga
Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB
Johnson & Johnson has submitted a Biologics License Application (BLA) to the FDA for nipocalimab, seeking its first global approval for generalized myasthenia gravis (gMG). This submission follows... 
Via Benzinga
Exposures Product Safety
12 Dividend Stocks to Earn Income Every Month
Get paid a dividend on a monthly basis. 
Via The Motley Fool
3 Ways the Democratic Party's Platform Could Impact Biotech and Pharma Stocks if Implemented
There's no reason to succumb to gloom and doom here. 
Via The Motley Fool
Johnson Johnson-Partner Addex Therapeutics Selects Investigational Compound For Substance Use Disorder
Addex Therapeutics stock surged after announcing clinical candidate selection with Indivior for substance use disorder treatment. Addex could receive up to $330 million plus royalties under the... 
Via Benzinga
Jim Cramer Believes In Dell CEO, Doesn't Like B&G Foods
Cramer gives his take on E.l.f Beauty, Acadia Pharmaceuticals, B&G Foods, Lucid, SoFi, Dell, Johnson & Johnson, UWM and Symbotic. 
Via Benzinga
Here Are 2 Great Vanguard Dividend ETFs: Which Is Right For You?
Now could be a great time to buy excellent dividend stocks, but these two ETFs have different approaches. 
Via The Motley Fool
Topics ETFs
Meet Wall Street's Safest Dividend Stock: A Small-Cap Company Few Investors Know Exists
This relative unknown hasn't missed a dividend payment to its shareholders in more than 200 years! 
Via The Motley Fool
Johnson & Johnson Aims New Policy For Hospital Payments Under 340B Drug Discount Program Related To Its Flagship Blood Thinner And Arthritis Drugs
Johnson & Johnson announced major changes to its 340B pricing for Stelara and Xarelto, effective October 15. Disproportionate share hospitals will need to purchase these drugs at full price initially... 
Via Benzinga
Johnson & Johnson Seeks Resolution With Plaintiffs, Pushes To Finalize $6.5B Talc Settlement
Johnson & Johnson is negotiating with plaintiffs' lawyers opposing its $6.48 billion talc settlement, 
Via Benzinga
Johnson & Johnson’s Executive Vice President, Chief Human Resources Officer Peter Fasolo to Retire; Kristen Mulholland Named Chief Human Resources Officer, Effective October 1, 2024
From Johnson & Johnson
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.